News: IMM Immutep Says Co Entered Into Clinical Trial Collaboration And Supply Agreement, page-17

IMM got metioned in trading day summary of The Australian:

‘Which Aussie biotech is in with big pharma?

Aussie biotech Immutep has secured the backing of pharma giants Merck and Pfizer to test its cancerous tumour-fighting drug in a clinical trial.

Immutep, of market cap just $124 million, has signed an agreement with European drug companies for an early phase clinical trial to test the benefits of combining its immune-stimulating drug, eftilagimod alpha (efti) with avelumab, a targeted cancer therapy being developed by Merck and Pfizer.

Shares in the stock surged to touch two-year highs of 4.5c - up almost 10 per cent on the news.

“We feel that this new collaboration, with these industry leaders, further supports our hypothesis that there is a potentially meaningful therapeutic benefit in combining eftilagimod alpha with a checkpoint inhibitor in the treatment of cancer,” chief Mark Voigt said.’